Results 91 to 100 of about 435,631 (309)

Supplementary table 3 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

, 2023
<p>Supplementary table 3. Multivariate model for Overall Survival (Cytotoxic Agents)</p>
Stan B. Kaye, Jaap Verweij, Josep Tabernero, Jean Charles Soria, Richard H. Wilson, Ruth Plummer, Jeffrey Evans, Emile Voest, Nicolas Penel, Jan H.M. Schellens, Silvia Marsoni, Patrick Schöffski, Andre T. Brunetto, Elisa Gallerani, Gianluca Del Conte, Rafael Morales-Barrera, Philippe A. Cassier, Carlos Gomez-Roca, David Olmos, Victor Moreno García   +19 more
openaire   +1 more source

Design and analysis strategies for robust microbiome ageing research

FEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik, İsmail Güderer, Yi Wang, Tayyaba Alvi, Prasoon Pandey, Handan Melike Dönertaş   +5 more
wiley   +1 more source

An Innovative Disease‐Drug‐Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate

Clinical and Translational Science, 2020
As with other psychiatric disorders, development of drugs to treat binge‐eating disorder (BED) has been hampered by high placebo response and dropout rates in randomized controlled trials (RCTs).
Shamir N. Kalaria, Susan L. McElroy, Jogarao Gobburu, Mathangi Gopalakrishnan   +3 more
doaj   +1 more source

Dose-response relationship of MSCs as living Bio-drugs in HFrEF patients: a systematic review and meta-analysis of RCTs

Stem Cell Research & Therapy
Abstract Background Mesenchymal stem cells (MSCs) have emerged as living biodrugs for myocardial repair and regeneration. Recent randomized controlled trials (RCTs) have reported that MSC-based therapy is safe and effective in heart failure patients; however, its dose-response relationship has yet to be established.
Ziyad T. Ahmed, Maha Saad Zain Al-Abeden, Mohamed Ghaith Al Abdin, Mohamad Ayham Muqresh, Ghazi I. Al Jowf, Lars M. T. Eijssen, Khawaja Husnain Haider   +6 more
openaire   +3 more sources

Supplementary table 2 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

, 2023
<p>Supplementary table 2. Multivariate model for overall survival (Molecularly Targeted Agents).</p>
Stan B. Kaye, Jaap Verweij, Josep Tabernero, Jean Charles Soria, Richard H. Wilson, Ruth Plummer, Jeffrey Evans, Emile Voest, Nicolas Penel, Jan H.M. Schellens, Silvia Marsoni, Patrick Schöffski, Andre T. Brunetto, Elisa Gallerani, Gianluca Del Conte, Rafael Morales-Barrera, Philippe A. Cassier, Carlos Gomez-Roca, David Olmos, Victor Moreno García   +19 more
openaire   +1 more source

Investigating transcription factor dynamics in health and disease using FRAP

FEBS Letters, EarlyView.
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj, Carolina Vazquez Garzon, Jose Joaquin Velasco, Janine N. Post   +3 more
wiley   +1 more source

Geometric construction of optimal designs for dose-responsemodels with two parameters [PDF]

In dose-response studies, the dose range is often restricted due to concerns over drug toxicity and/or efficacy. We derive optimal designs for estimating the underlying dose-response curve for a restricted or unrestricted dose range with respect to a ...
Zhu, Wei, Dette, Holger, Biedermann, Stefanie   +2 more
core  

Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology [PDF]

, 2014
Pharmacokinetic/pharmacodynamic (PKPD) modelling is used to describe and quantify dose-concentration-effect relationships. Within paediatric studies in infectious diseases and immunology these methods are often applied to developing guidance on ...
Hoare, RL, Germovsek, Eva, Standing, JF, Standing, Joseph F., Lewis, J, Barker, Charlotte I.S., Lewis, Joanna, Lestner, Jodi M., Hoare, Rollo L., Barker, CI, Germovsek, E, Lestner, JM   +11 more
core   +1 more source

The 90% minimum effective volume and concentration of lidocaine for ultrasound-guided stellate ganglion blocks in adults: a biased-coin design, up-and-down sequential allocation trial [PDF]

Korean Journal of Anesthesiology
Background As ultrasound imaging technology matured, stellate ganglion blocks (SGBs) have become increasingly precise and safe, and their use in clinical practice has become widespread. However, the 90% minimum effective volume (MEV90) and concentration (
Shujun Sun, Qinghua Yin, Jiwei Shen, Yang Lv, Long Li, Zhangyan Mao, Yun Lin, Xiangdong Chen, Dong Yang   +8 more
doaj   +1 more source

Supplementary Figure 1 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

, 2023
<p>Supplementary Figure 1. Study flowchart</p>
Stan B. Kaye, Jaap Verweij, Josep Tabernero, Jean Charles Soria, Richard H. Wilson, Ruth Plummer, Jeffrey Evans, Emile Voest, Nicolas Penel, Jan H.M. Schellens, Silvia Marsoni, Patrick Schöffski, Andre T. Brunetto, Elisa Gallerani, Gianluca Del Conte, Rafael Morales-Barrera, Philippe A. Cassier, Carlos Gomez-Roca, David Olmos, Victor Moreno García   +19 more
openaire   +1 more source